HomeScienceMIRAM® KitClinical StudiesNewsTeamCareersContact

Press Releases

All newsPress Releases
Study in JCO Precision Oncology shows promising results supporting the use of glycosaminoglycan profiles (GAGomes) for monitoring and predicting response in patients with metastatic renal cell carcinoma

Study in JCO Precision Oncology shows promising results supporting the use of glycosaminoglycan profiles (GAGomes) for monitoring and predicting response in patients with metastatic renal cell carcinoma

Mar 15, 2023
Double multi-cancer detection rate shown in the earliest stage using Elypta MIRAM® kit

Double multi-cancer detection rate shown in the earliest stage using Elypta MIRAM® kit

Dec 7, 2022
Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test

Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test

Jun 20, 2022
Elypta launches Multi-Cancer Early Detection study to measure metabolic GAGome levels in adults at high risk of cancer in collaboration with the University of Leeds and Yorkshire Cancer Research

Elypta launches Multi-Cancer Early Detection study to measure metabolic GAGome levels in adults at high risk of cancer in collaboration with the University of Leeds and Yorkshire Cancer Research

Apr 4, 2022
Elypta launches Multi-Cancer Early Detection screening study measuring metabolic GAGome levels in asymptomatic adults

Elypta launches Multi-Cancer Early Detection screening study measuring metabolic GAGome levels in asymptomatic adults

Feb 15, 2022
Pivotal AUR87A study of GAGome-based liquid biopsy for kidney cancer recurrence opens 26th site

Pivotal AUR87A study of GAGome-based liquid biopsy for kidney cancer recurrence opens 26th site

Dec 15, 2021
Elypta extends range of GAGome-based liquid biopsy applications

Elypta extends range of GAGome-based liquid biopsy applications

Dec 8, 2021
Elypta launches research service for glycosaminoglycan profiling

Elypta launches research service for glycosaminoglycan profiling

Feb 3, 2021
Elypta granted US patent for its liquid biopsy method based on cancer metabolism

Elypta granted US patent for its liquid biopsy method based on cancer metabolism

Jan 28, 2021
First patient enrolled in Elypta’s pioneering AUR87A renal cell carcinoma liquid biopsy trial

First patient enrolled in Elypta’s pioneering AUR87A renal cell carcinoma liquid biopsy trial

Feb 11, 2020
Elypta raises €6.1 million in a late seed round led by Industrifonden

Elypta raises €6.1 million in a late seed round led by Industrifonden

Jan 23, 2020
Elypta awarded €2.35 million from Horizon 2020 SME instrument

Elypta awarded €2.35 million from Horizon 2020 SME instrument

Feb 4, 2019
Backed by
Industrifonden LogoChalmers VenturesNorrsken VCEU

Advance cancer detection with us

Collaborations

We welcome partnerships with academia to explore clinical applications as well as industry for the development of companion diagnostics.

Learn more

Investors

We welcome interest from investors and are happy to provide more information on our plans on request.

Get in touch

Join the team

We are always looking to interact with top talents interested in joining our development team.

Learn more
+46 (0)8 520 27 885info@elypta.com

Elypta AB, Nanna Svartz väg 4, 171 65 Solna, Sweden

ScienceMIRAM® KitClinical StudiesNewsTeamCareersContact